High prevalence of clinical spondyloarthritis features in patients with hidradenitis suppurativa

Rondags, Angelique; Straalen, Kelsey R. van; Arends, Suzanne; Zee, Hessel H. van der; Prens, Errol P.; Spoorenberg, A.; Hórvath, Barbara

doi:10.1016/j.jaad.2018.06.028

Cited by 11 publications

(17 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Arthropathy has been associated with both classical and syndromic HS 115,122,145–148 . The prevalence of spondyloarthritis (SpA) in HS varies greatly among a small number of published studies 146–148 . The largest prospective study ( n = 640) estimated a prevalence of 3.7% based upon the European Spondyloarthropathy Study Group (ESSG) critieria 148 .…”

Section: Comorbiditiesmentioning

confidence: 99%

“…The largest prospective study ( n = 640) estimated a prevalence of 3.7% based upon the European Spondyloarthropathy Study Group (ESSG) critieria 148 . Two smaller studies ( n = 416 and 39) produced much higher prevalence values (28.2% and >50%, respectively), likely due to different study designs (cross‐sectional vs. prospective) and criteria used (Assessment of SpA international Society criteria instead of the ESSG criteria) 146,147 . One in particular relied on patient‐reported data – this might explain the prevalence of >50% 147 …”

Section: Comorbiditiesmentioning

confidence: 99%

See 1 more Smart Citation

Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life

Nguyen

Damiani

Orenstein

et al. 2020

Acad Dermatol Venereol

244

248

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease that severely impairs patients' quality of life. It is characterized by recurrent painful nodules, abscesses and draining sinus tracts in primarily intertriginous areas. We aimed to review the most up‐to‐date information regarding the epidemiology, clinical presentation, diagnostic studies, pathogenesis, comorbidities and quality of life of patients with hidradenitis suppurativa. We performed a systematic search of Medline, Embase database (from inception to September 2019) and review of bibliographies without restrictions on year or language. HS has an estimated global prevalence of 0.00033–4.1% (but most likely 0.7–1.2% in the European‐US population). Patients still experience a significant diagnostic delay, up to several years. In the absence of pathognomonic tests, the diagnosis of HS is made from clinical observation and the disease narrative. Phenotypic variation renders diagnosis and severity assessment difficult. Ultrasound imaging is an emerging assessment tool for deep‐seated lesions. The Hurley Staging System is still widely used in severity rating. Follicular hyperkeratosis and dilatation, follicular rupture and chronic inflammation with architectural tissue changes have been implicated in the pathogenesis of HS. HS has been associated with metabolic syndrome and other risk factors for cardiovascular disease, diabetes mellitus type II, polycystic ovarian syndrome, depression, suicide and substance use disorders. It has been linked to other immune‐mediated diseases such as inflammatory bowel disease and spondyloarthropathy. Pain, pruritus, malodour, low self‐esteem, sleep and sexual dysfunctions, and poor mental health are chronic symptoms or consequences of uncontrolled disease. HS is an under‐diagnosed and under‐treated disease with a profound negative impact on patients' quality of life. In the light of its associated comorbidities, an interdisciplinary management approach may be needed to ensure the best outcomes.

show abstract

Section: Comorbiditiesmentioning

confidence: 99%

Section: Comorbiditiesmentioning

confidence: 99%

Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life

Nguyen

Damiani

Orenstein

et al. 2020

Acad Dermatol Venereol

244

248

View full text Add to dashboard Cite

show abstract

“…Furthermore, several inflammatory mediators reach the blood and may contribute to comorbid disorders (14,15). In fact, HS is frequently associated with both spondyloarthritis and metabolic alterations, which increases the risk of cardiovascular diseases and reduces life expectancy (16)(17)(18)(19).…”

Section: Introductionmentioning

confidence: 99%

Features Associated With Quality of Life Impairment in Hidradenitis Suppurativa Patients

et al. 2021

View full text Add to dashboard Cite

Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with an adverse impact on patients' quality of life (QoL).Objectives: To quantify QoL impairment in patients in Germany suffering from HS and to identify the parameters associated with QoL impairment.Methods: A non-interventional, cross-sectional, mono-centric study with 500 HS patients. QoL data (measured using the Dermatology Life Quality Index; DLQI) and demographic, anamnestic, clinical, and blood parameters were collected. All patients were examined by dermatologists that documented the skin alterations. QoL data from 462 HS patients were available and evaluated.Results: The mean (± standard deviation) DLQI score of HS patients was 13.18 ± 7.99. Approximately 40% and 20% of HS patients declared very large and extremely large QoL impairment, respectively. The degree of QoL disturbance correlated with the severity of skin alterations, blood leucocyte count and, in particular, with anogenital localization and the presence of nodules and fistulas. Furthermore, QoL impairment was associated with specific comorbidities, such as adiposity and back pain, but not with HS family history. QoL impairment was not influenced by whether or not the patients had undergone resection surgery or antibiotic treatment but was more severe in HS patients that had undergone abscess lancing compared to patients without such treatment in the past.Limitations: It was a mono-centric study and most data were obtained from self-administered patient questionnaires. The association of QoL with type of treatment was analyzed for abscess lancing, resection surgery, and antibiotic treatment. Further therapeutic modalities recommended in the guidelines were not investigated.Conclusion: A profound impairment in QoL was present in patients with HS, and this was higher than that observed in other studied dermatoses. The degree of impairment correlated with the extent of cutaneous and some extra-cutaneous alterations. Surgical and conventional medicamentous therapies of HS were not associated with long-lasting reduction of QoL impairment. Our data support the implementation of patient-reported outcome measures for the assessment of therapy responses.

show abstract

“…HS is associated with numerous comorbidities. In addition to polycystic ovary syndrome [6], chronic inflammatory bowel diseases [3], spondylarthritis [18], or depression [13]. The metabolic syndrome [15] also plays an important role in patients with HS.…”

Section: Introductionmentioning

confidence: 99%

Prevalence and cutaneous comorbidities of hidradenitis suppurativa in the German working population

2020

View full text Add to dashboard Cite

The association of hidradenitis suppurativa with other skin diseases has not yet been investigated in larger studies based on dermatological exams. The objectives of this study are to determine the prevalence and cutaneous comorbidities of hidradenitis suppurativa in the German working population. Between 2014 and 2017, 20,112 people in 343 German companies were examined for the presence of clinical features of hidradenitis suppurativa within the framework of a cross-sectional epidemiological study based on whole-body examinations. In addition, all cutaneous comorbidities were recorded. Point prevalence was calculated and the differences between individuals with and without hidradenitis suppurativa were determined by bivariate analysis. All statistical procedures were performed using SPSS 23.0 for Windows. Of 20,112 people examined, mean age was 43.6 ± 10.5 years; 52.3% were male. In total, n = 57 people (0.3%) with hidradenitis suppurativa were identified; 61.4% (n = 35) being male. In addition, non-inflammatory hidradenitis suppurativa-related lesions were found in 674 other individuals. In a bivariate comparison, patients with hidradenitis suppurativa showed significantly more frequently the following cutaneous comorbidities: acne vulgaris, psoriasis, seborrhoeic dermatitis, excoriations, and folliculitis. We determined a point prevalence of hidradenitis suppurativa of 0.3%. Since we have examined the working population, the healthy worker effect, which could have led to underestimation of prevalence, cannot be ruled out. The point prevalence of 0.3% for employed people in Germany and a prevalence of 3.0% for inflammatory and non-inflammatory hidradenitis suppurativarelated lesions show that hidradenitis suppurativa is an important disease for the whole health system.

show abstract

High prevalence of clinical spondyloarthritis features in patients with hidradenitis suppurativa

Cited by 11 publications

References 5 publications

Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life

Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life

Features Associated With Quality of Life Impairment in Hidradenitis Suppurativa Patients

Prevalence and cutaneous comorbidities of hidradenitis suppurativa in the German working population

Contact Info

Product

Resources

About